[go: up one dir, main page]

BRPI0818165B8 - método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura - Google Patents

método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura

Info

Publication number
BRPI0818165B8
BRPI0818165B8 BRPI0818165A BRPI0818165A BRPI0818165B8 BR PI0818165 B8 BRPI0818165 B8 BR PI0818165B8 BR PI0818165 A BRPI0818165 A BR PI0818165A BR PI0818165 A BRPI0818165 A BR PI0818165A BR PI0818165 B8 BRPI0818165 B8 BR PI0818165B8
Authority
BR
Brazil
Prior art keywords
nucleic acid
selection agent
cell
culture medium
heterologous immunoglobulin
Prior art date
Application number
BRPI0818165A
Other languages
English (en)
Inventor
Stern Anne
Kopetzki Erhard
Knoetgen Hendrik
Goepfert Ulrich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818165(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0818165A2 publication Critical patent/BRPI0818165A2/pt
Publication of BRPI0818165B1 publication Critical patent/BRPI0818165B1/pt
Publication of BRPI0818165B8 publication Critical patent/BRPI0818165B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura, anti-abeta, antisseleção p, anti-il-13ralfa, bem como conjugado de anticorpo anticd4. a presente invenção refere-se a um método para a produção recombinante de uma imunoglobulina heteróloga secretada em uma célula cho, compreendendo as seguintes etapas: i) proporcionar uma célula cho, a qual está adaptada ao crescimento em cultura em suspensão, adaptada ao crescimento em meio sem soro, sem micoplasma, e sem vírus, ii) proporcionar um vetor compreendendo uma origem de replicação procariótica, um primeiro ácido nucleico conferindo resistência a um agente de seleção procariótico, um segundo ácido nucleico codificando a cadeia longa da dita imunoglobulina heteróloga, um terceiro ácido nucleico codificando a cadeia curta da dita imunoglobulina heteróloga, um quarto ácido nucleico conferindo resistência a um agente de seleção eucariótico, iii) transfectar a dita célula cho, em que a dita transfecção compreende a) transfectar a dita célula cho com o dito vetor compreendendo um quarto ácido nucleico conferindo resistência a um primeiro agente de seleção eucariótico, b) selecionar uma célula cho por crescimento em um meio de cultivo contendo o dito primeiro agente de seleção eucariótico, c) transfectar a dita célula cho selecionada com o dito vetor compreendendo um quarto ácido nucleico conferindo resistência a um segundo agente de seleção eucariótico diferente do dito primeiro agente de seleção eucariótico, d) selecionar uma célula cho por crescimento selecionado em um meio de cultivo contendo o dito primeiro e o dito segundo agentes de seleção eucarióticos, iv) cultivar a dita célula cho transfectada em um meio na presença dos ditos primeiro e segundo agentes de seleção eucarióticos, sob condições adequadas para a expressão dos ditos segundo e terceiro ácidos nucleicos, e v) recuperar a dita imunoglobulina heteróloga secretada do meio de cultivo.
BRPI0818165A 2007-10-12 2008-10-09 método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura BRPI0818165B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07019999.7 2007-10-12
EP07019999 2007-10-12
PCT/EP2008/008523 WO2009046978A1 (en) 2007-10-12 2008-10-09 Protein expression from multiple nucleic acids

Publications (3)

Publication Number Publication Date
BRPI0818165A2 BRPI0818165A2 (pt) 2014-10-14
BRPI0818165B1 BRPI0818165B1 (pt) 2020-10-27
BRPI0818165B8 true BRPI0818165B8 (pt) 2021-05-25

Family

ID=39204855

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0818165A BRPI0818165B8 (pt) 2007-10-12 2008-10-09 método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
BRPI0818536-0A2A BRPI0818536A2 (pt) 2007-10-12 2008-10-13 Linhagem celular cho-k1

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0818536-0A2A BRPI0818536A2 (pt) 2007-10-12 2008-10-13 Linhagem celular cho-k1

Country Status (20)

Country Link
US (5) US8771988B2 (pt)
EP (4) EP2592147A1 (pt)
JP (2) JP5642549B2 (pt)
KR (2) KR101280704B1 (pt)
CN (2) CN101815786A (pt)
AU (2) AU2008309934B2 (pt)
BR (2) BRPI0818165B8 (pt)
CA (2) CA2701646C (pt)
DK (1) DK2592148T3 (pt)
ES (1) ES2695999T3 (pt)
HR (1) HRP20181833T1 (pt)
HU (1) HUE039950T2 (pt)
IL (2) IL203900A (pt)
LT (1) LT2592148T (pt)
MX (3) MX338036B (pt)
PL (1) PL2592148T3 (pt)
PT (1) PT2592148T (pt)
SI (1) SI2592148T1 (pt)
TR (1) TR201816045T4 (pt)
WO (2) WO2009046978A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2563514C2 (ru) * 2009-06-11 2015-09-20 Интер-Юниверсити Рисерч Инститьют Корпорейшн Рисерч Организейшн Оф Информейшн Энд Системз Способ получения белка
AU2010269978B2 (en) * 2009-07-08 2016-11-03 Kymab Limited Animal models and therapeutic molecules
KR20180010324A (ko) 2009-08-11 2018-01-30 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
AU2010317609A1 (en) * 2009-11-16 2012-07-05 Acyte Biotech Pty Ltd Recombinant antibody vector
US9096879B2 (en) * 2009-11-24 2015-08-04 Biogen Ma Inc. Method of supplementing culture media to prevent undesirable amino acid substitutions
AU2011246504B2 (en) 2010-04-26 2013-09-26 Novartis Ag Improved cell culture medium
US9068198B2 (en) 2010-09-15 2015-06-30 Medimmune Limited Chinese hamster ovary cell line
HUE047228T2 (hu) 2010-11-05 2020-04-28 Zymeworks Inc Stabil heterodimer antitest-kialakítás az FC doménben mutációval
DK3311661T3 (da) 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
MX355625B (es) 2011-12-22 2018-04-25 Hoffmann La Roche Organizacion de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
EP2674495A1 (en) * 2012-06-14 2013-12-18 Sanofi CHO expression system
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR20210037745A (ko) 2013-03-15 2021-04-06 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
PT3074424T (pt) 2013-11-27 2025-05-29 Zymeworks Bc Inc Construções de ligação a antigénio biespecíficas direcionadas a her2
US11124760B2 (en) 2014-03-24 2021-09-21 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
EP3140392B1 (en) * 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
JP6333378B2 (ja) * 2014-07-16 2018-05-30 Ｈｅａｒｔｓｅｅｄ株式会社 新規未分化幹細胞除去および心筋純化精製培地
PL3289092T3 (pl) * 2015-04-27 2020-07-13 Momenta Pharmaceuticals, Inc. Sposób wytwarzania białka terapeutycznego
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
ES2823173T3 (es) 2016-01-27 2021-05-06 Just Biotherapeutics Inc Promotor híbrido y usos del mismo
TW201738272A (zh) 2016-04-15 2017-11-01 艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
GB201718088D0 (en) * 2017-11-01 2017-12-13 Autolus Ltd Vectors
CN111019881B (zh) * 2019-11-21 2020-10-09 中山康天晟合生物技术有限公司 一种适应高渗透压、高铵离子、高乳酸生长环境的细胞
US20230265204A1 (en) 2020-04-24 2023-08-24 Hoffmann-La Roche Inc. Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112920995A (zh) * 2021-03-31 2021-06-08 赵峻岭 一种间充质干细胞培养血清加油包及其应用
CN115521919B (zh) * 2022-11-04 2023-04-11 广州誉衡生物科技有限公司 一种调节pd-1抗体和lag-3抗体酸性电荷异构体的cho细胞培养方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912038A (en) 1984-12-11 1990-03-27 California Biotechnology Inc. Recombinant DNA sequence encoding alveolar surfactant protein
DE3688418T2 (de) 1985-02-13 1993-08-26 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
EP0368926A4 (en) 1987-07-16 1991-11-27 Codon Transfected cells containing plasmids having genes oriented in opposing directions and methods of obtaining the same
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
EP0319206A3 (en) 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
WO1989010959A1 (en) * 1988-05-06 1989-11-16 Codon Supertransformants for high expression rates in eukaryotic cells
DD287531A5 (de) 1988-06-16 1991-02-28 Akademie Der Wissenschaften,De Verfahren zur herstellung von humanem wachstumshormon (sth) in tierischen zellen
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
JP2859679B2 (ja) * 1990-03-01 1999-02-17 協和醗酵工業株式会社 新規細胞株
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JP3150340B2 (ja) 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
GB9114468D0 (en) * 1991-07-04 1991-08-21 Wellcome Found Antibody production
EP0569678A3 (de) 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
FI955261L (fi) * 1993-05-04 1996-01-03 Cytel Corp P-selektiinin vasta-aineita ja niiden käyttö
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
WO1995017513A1 (en) * 1993-12-23 1995-06-29 Novo Nordisk A/S Retransformation of filamentous fungi
US5719050A (en) 1993-12-24 1998-02-17 Eiken Chemical Co., Ltd. Animal cell culturing media containing N-acetyl-L-glutamic acid
US5726041A (en) 1995-08-30 1998-03-10 Gentest Corporation Method for detecting a receptor-ligand complex using a cytochrome P450 reporter gene
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
AU5874798A (en) 1997-01-31 1998-08-25 Biovation Limited Vaccination methods and molecules
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
WO1999026463A2 (en) 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
EP1066371A1 (en) 1998-03-18 2001-01-10 Pharmacopeia, Inc. Eukaryotic cells stably expressing genes from multiple transfected episomes
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
TW570977B (en) 1998-12-07 2004-01-11 Li-Wei Hsu An expression system for producing recombinant human erythropoietin, method for purifying secreted human erythropoietin and uses thereof
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
DE19920712A1 (de) 1999-05-05 2000-11-09 Rhein Biotech Proz & Prod Gmbh Verfahren zum Herstellen eines rekombinanten Proteines
US6413744B1 (en) * 1999-08-25 2002-07-02 Immunex Corporation Methods and host cells for improved cell culture
AUPQ422399A0 (en) 1999-11-24 1999-12-16 University Of New South Wales, The Method of screening transformed or transfected cells
DE10036491A1 (de) * 2000-07-25 2002-02-07 Roche Diagnostics Gmbh Expression von Alkalischer Phosphatase in Hefe
AU2002358047A1 (en) 2001-11-28 2003-06-10 Sandoz Ag Method for producing a recombinant polypeptide
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
AU2003213791A1 (en) 2002-03-05 2003-09-22 Vitra Bioscience, Inc. Multiplexed cell transfection using coded carriers
DE10213201A1 (de) 2002-03-25 2003-10-16 Roche Diagnostics Gmbh Erzeugung von schwach aktiven oder inaktiven Mutanten von Alkalischer Phosphatase und deren Expression in Hefe
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
HRP20130440T1 (en) 2004-04-13 2013-06-30 F. Hoffmann - La Roche Ag Anti-p-selectin antibodies
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
MX2008011785A (es) * 2006-03-16 2008-09-25 Genentech Inc Metodos de tratamiento de lupus utilizando anticuerpos cd4.
US8227576B2 (en) * 2006-03-30 2012-07-24 Glaxo Group Limited Antibodies against amyloid-β peptide
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.

Also Published As

Publication number Publication date
BRPI0818165B1 (pt) 2020-10-27
KR20100059969A (ko) 2010-06-04
MX2010003622A (es) 2010-04-14
WO2009047007A1 (en) 2009-04-16
JP2010540583A (ja) 2010-12-24
HRP20181833T1 (hr) 2019-01-11
EP2207881A1 (en) 2010-07-21
AU2008309881A1 (en) 2009-04-16
US20140335609A1 (en) 2014-11-13
HUE039950T2 (hu) 2019-02-28
DK2592148T3 (en) 2018-12-10
EP2592148B1 (en) 2018-09-12
LT2592148T (lt) 2018-12-10
PT2592148T (pt) 2018-11-12
KR20100059967A (ko) 2010-06-04
CA2701646C (en) 2019-02-26
CN101821394A (zh) 2010-09-01
US20100249379A1 (en) 2010-09-30
JP2011500009A (ja) 2011-01-06
EP2592147A1 (en) 2013-05-15
JP5642549B2 (ja) 2014-12-17
IL203902A0 (en) 2011-07-31
TR201816045T4 (tr) 2018-11-21
MX338036B (es) 2016-03-31
US20100221781A1 (en) 2010-09-02
BRPI0818536A2 (pt) 2014-10-14
US20170166923A1 (en) 2017-06-15
AU2008309934B2 (en) 2014-03-06
US20190233842A1 (en) 2019-08-01
AU2008309934A1 (en) 2009-04-16
BRPI0818165A2 (pt) 2014-10-14
CA2701646A1 (en) 2009-04-16
US9428766B2 (en) 2016-08-30
PL2592148T3 (pl) 2019-01-31
IL203900A (en) 2014-08-31
IL203900A0 (en) 2011-07-31
ES2695999T3 (es) 2019-01-11
WO2009046978A1 (en) 2009-04-16
MX2010003620A (es) 2010-04-14
EP2592148A1 (en) 2013-05-15
EP2207882A1 (en) 2010-07-21
KR101280704B1 (ko) 2013-07-01
SI2592148T1 (sl) 2018-12-31
US8771988B2 (en) 2014-07-08
CA2701677A1 (en) 2009-04-16
CN101815786A (zh) 2010-08-25

Similar Documents

Publication Publication Date Title
BRPI0818165B8 (pt) método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
Liu et al. Development of a new method for genetic transformation of the green alga Chlorella ellipsoidea
Rasala et al. The microalga Chlamydomonas reinhardtii as a platform for the production of human protein therapeutics
EP4291202A1 (en) Nuclease-guided non-ltr retrotransposons and uses thereof
WO2021102042A1 (en) Retrotransposons and use thereof
BR112017007770A2 (pt) cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
BRPI0922572A2 (pt) método para cultivar células pluripotentes, cultura de células de mamífero pluripotentes, meio de cultura de célula, célula animal pluripotente isolada, e, método para aumentar a pluripotência de uma célula de mamífero.
BRPI1011227A8 (pt) microorganismos e métodos para a biossíntese de adipato, hexametilenodiamina e ácido 6-aminocapróico.
HRP20240920T1 (hr) Postupak za proizvodnju glikoziliranog imunoglobulina
EA201490631A1 (ru) Способы культивирования клеток млекопитающих для получения белка
BR112013028621A2 (pt) "microalgas oleaginosas recombinantes, método para produzir biomassa de microalga ou um produto produzido da biomassa, e método para produzir uma composição lipídica de microalga".
Kang et al. Heterologous overexpression of sfCherry fluorescent protein in Nannochloropsis salina
MX2021000209A (es) Metodos y productos para transfeccion de celulas.
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
SG179561A1 (en) Composition and method for imaging stem cells
Diamond et al. Instability of extrachromosomal DNA transformed into the diatom Phaeodactylum tricornutum
Kudoh et al. Prerequisite for highly efficient isoprenoid production by cyanobacteria discovered through the over-expression of 1-deoxy-d-xylulose 5-phosphate synthase and carbon allocation analysis
BRPI0906241B8 (pt) molécula de ácido nucleico, gene quimérico, vetor e método de transformação de uma célula bacteriana
NZ711654A (en) Improved recombinant protein expression using a hybrid chef1 promoter
AU2016281666B2 (en) Fusion constructs as protein over-expression vectors
BRPI1006628B8 (pt) método para produzir uma enzima lipolítica
BR112015012408A2 (pt) célula somática geneticamente modificada, método para produzir um animal não humano, e, ovócito clonado de um animal não humano
BRPI1008762B8 (pt) métodos para seleção de células de mamífero expressando uma proteína heteróloga, para produzir um produto de interesse e uso de um meio de cultura seletivo
Kalidas et al. A Gateway® compatible vector for gene silencing in bloodstream form Trypanosoma brucei
WO2022076830A1 (en) Type i crispr-associated transposase systems

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF